medical innovation

India has introduced its first indigenous antibiotic, Nafithromycin, to address the rising threat of drug-resistant bacterial infections, particularly community-acquired bacterial pneumonia (CABP). Developed by Wockhardt Ltd with support from BIRAC, this new antibiotic provides ten times the effectiveness of azithromycin, the current standard, and ensures better lung exposure. Its once-daily dose for three days improves compliance and outcomes. As antimicrobial resistance rises globally, Nafithromycin represents a significant step forward, offering a faster, safer, and more effective treatment for drug-resistant bacterial infections.